Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 6:12 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 6:12 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Zacks News
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session
by Zacks Equity Research
Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Do Options Traders Know Something About Akebia (AKBA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
by Zacks Equity Research
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
Implied Volatility Surging for Akebia (AKBA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health Continues to Strengthen Presence in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to offer improved health outcomes through plans to construct a new hospital in Florida, where it already boasts of a strong base.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AKBA) Outperforming Other Medical Stocks This Year?
Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).
How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -35.56% and -27.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -4.76% and -13.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.